Date: 2012-03-13

Type of information: Collaboration agreement

Compound: biomarkers

Company: GSK (UK) Epistem (UK)

Therapeutic area:

Type agreement:


Action mechanism:

Disease: fibrosis


Epistem has announced a three year biomarker collaboration with GSK in the field of fibrosis research. The collaboration will focus on identifying key characteristics of diseased fibrotic tissue on which Epistem will apply its proprietary RNA-Amp™ technology to facilitate building an in depth understanding of the disease.
RNA-Amp is highly sensitive amplification technology which is able to provide gene expression information from small tissue samples and low of numbers of cells e.g. those obtained from the bulb of cells at the base of a single hair follicle, as well as laser captured microdissected samples.

Financial terms:

Latest news:

Is general: Yes